|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
|
|
2
|
Palmieri G, Paliogiannis P, Scognamillo F,
et al: Colorectal cancer epidemiology in an area with a spontaneous
screening program. Acta Medica Mediterr. 29:231–234. 2013.
|
|
3
|
National Cancer Institute. Cancer Trends
Progress Report - 2011/2012 Update. http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2011&chid=105&coid=1026&mid=.
Accessed December 5, 2013
|
|
4
|
Yabroff KR, Mariotto AB, Feuer E and Brown
ML: Projections of the costs associated with colorectal cancer care
in the United States, 2000–2020. Health Econ. 17:947–959. 2008.
|
|
5
|
Edwards BK, Ward E, Kohler BA, et al:
Annual report to the nation on the status of cancer, 1975–2006,
featuring colorectal cancer trends and impact of interventions
(risk factors, screening, and treatment) to reduce future rates.
Cancer. 116:544–573. 2010.
|
|
6
|
Jorissen RN, Walker F, Pouliot N, et al:
Epidermal growth factor receptor: mechanisms of activation and
signaling. Exp Cell Res. 284:31–53. 2003.
|
|
7
|
Yuan ZX, Wang XY, Qin QY, et al: The
prognostic role of BRAF mutation in metastatic colorectal cancer
receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS
One. 8:e659952013.
|
|
8
|
Malumbres M and Barbacid M: RAS Oncogenes:
the first 30 years. Nat Rev Cancer. 3:459–485. 2003.
|
|
9
|
Heinemann V, Stintzing S, Kirchner T,
Boeck S and Jung A: Clinical relevance of EGFR- and KRAS-status in
colorectal cancer patients treated with monoclonal antibodies
directed against the EGFR. Cancer Treat Rev. 35:262–271. 2009.
|
|
10
|
Bardelli A and Siena S: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. J Clin Oncol. 28:1254–1261. 2010.
|
|
11
|
Cunningham D, Humblet Y, Siena S, et al:
Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004.
|
|
12
|
Markowitz SD and Bertagnolli MM: Molecular
basis of colorectal cancer. N Engl J Med. 361:2404–2460. 2009.
|
|
13
|
Peltomäki P: Mutations and epimutations in
the origin of cancer. Exp Cell Res. 318:299–310. 2012.
|
|
14
|
Boland CR and Goel A: Microsatellite
instability in colorectal cancer. Gastroenterology. 138:2073–2087.
2010.
|
|
15
|
Jiang L, Huang M, Wang L, et al:
Overexpression of MEKK2 is associated with colorectal
carcinogenesis. Oncol Lett. 6:1333–1337. 2013.
|
|
16
|
Barzi A, Lenz AM, Labonte MJ and Lenz HJ:
Molecular pathways: estrogen pathway in colorectal cancer. Clin
Cancer Res. 19:5842–5848. 2013.
|
|
17
|
Vermaat JS, Nijman IJ, Koudijs MJ, et al:
Primary colorectal cancers and their subsequent hepatic metastases
are genetically different: implications for selection of patients
for targeted treatment. Clin Cancer Res. 18:688–699. 2012.
|
|
18
|
Palomba G, Colombino M, Contu A, et al:
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients
with colorectal carcinoma may vary in the same population: clues
from Sardinia. J Transl Med. 10:1782012.
|
|
19
|
Ciavarella S, Milano A, Dammacco F and
Silvestris F: Targeted therapies in cancer. BioDrugs. 24:77–88.
2010.
|
|
20
|
Winawer SJ: Natural history of colorectal
cancer. Am J Med. 106:3S–6S; discussion, 50S–51S. 1999.
|
|
21
|
Swanton C: Intratumor heterogeneity:
evolution through space and time. Cancer Res. 72:4875–4882.
2012.
|
|
22
|
Nassar A, Radhakrishnan A, Cabrero IA,
Cotsonis GA and Cohen C: Intratumoral heterogeneity of
immunohistochemical marker expression in breast carcinoma: a tissue
microarray-based study. Appl Immunohistochem Mol Morphol.
18:433–441. 2010.
|
|
23
|
Vignot S, Besse B, André F, Spano JP and
Soria JC: Discrepancies between primary tumor and metastasis: a
literature review on clinically established biomarkers. Crit Rev
Oncol Hematol. 84:301–313. 2012.
|
|
24
|
Shah SP, Morin RD, Khattra J, et al:
Mutational evolution in a lobular breast tumour profiled at single
nucleotide resolution. Nature. 461:809–813. 2009.
|
|
25
|
Ding L, Ellis MJ, Li S, et al: Genome
remodelling in a basal-like breast cancer metastasis and xenograft.
Nature. 464:999–1005. 2010.
|
|
26
|
Campbell PJ, Yachida S, Mudie LJ, et al:
The patterns and dynamics of genomic instability in metastatic
pancreatic cancer. Nature. 467:1109–1113. 2010.
|
|
27
|
Yachida S, Jones S, Bozic I, et al:
Distant metastasis occurs late during the genetic evolution of
pancreatic cancer. Nature. 467:1114–1117. 2010.
|
|
28
|
Goranova TE, Ohue M, Shimoharu Y and Kato
K: Dynamics of cancer cell subpopulations in primary and metastatic
colorectal tumors. Clin Exp Metastasis. 28:427–435. 2011.
|
|
29
|
Neumann J, Zeindl-Eberhart E, Kirchner T
and Jung A: Frequency and type of KRAS mutations in routine
diagnostic analysis of metastatic colorectal cancer. Pathol Res
Pract. 205:858–862. 2009.
|
|
30
|
Knijn N, Mekenkamp LJ, Klomp M, et al:
KRAS mutation analysis: a comparison between primary tumours and
matched liver metastases in 305 colorectal cancer patients. Br J
Cancer. 104:1020–1026. 2011.
|
|
31
|
Cejas P, López-Gómez M, Aguayo C, et al:
KRAS mutations in primary colorectal cancer tumors and related
metastases: a potential role in prediction of lung metastasis. PLoS
One. 4:e81992009.
|
|
32
|
Santini D, Loupakis F, Vincenzi B, et al:
High concordance of KRAS status between primary colorectal tumors
and related metastatic sites: implications for clinical practice.
Oncologist. 13:1270–1275. 2008.
|
|
33
|
Etienne-Grimaldi MC, Formento JL,
Francoual M, et al: K-Ras mutations and treatment outcome in
colorectal cancer patients receiving exclusive fluoropyrimidine
therapy. Clin Cancer Res. 14:4830–4835. 2008.
|
|
34
|
Park JH, Han SW, Oh DY, et al: Analysis of
KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary
tumors and paired metastases in determining benefit from cetuximab
therapy in colon cancer. Cancer Chemother Pharmacol. 68:1045–1055.
2011.
|
|
35
|
Watanabe T, Kobunai T, Yamamoto Y, et al:
Heterogeneity of KRAS status may explain the subset of discordant
KRAS status between primary and metastatic colorectal cancer. Dis
Colon Rectum. 54:1170–1178. 2011.
|
|
36
|
Molinari F, Martin V, Saletti P, et al:
Differing deregulation of EGFR and downstream proteins in primary
colorectal cancer and related metastatic sites may be clinically
relevant. Br J Cancer. 100:1087–1094. 2009.
|
|
37
|
Loupakis F, Pollina L, Stasi I, et al:
PTEN expression and KRAS mutations on primary tumors and metastases
in the prediction of benefit from cetuximab plus irinotecan for
patients with metastatic colorectal cancer. J Clin Oncol.
27:2622–2629. 2009.
|
|
38
|
Mariani P, Lae M, Degeorges A, et al:
Concordant analysis of KRAS status in primary colon carcinoma and
matched metastasis. Anticancer Res. 30:4229–4235. 2010.
|
|
39
|
Baldus SE, Schaefer KL, Engers R, et al:
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in
primary colorectal adenocarcinomas and their corresponding
metastases. Clin Cancer Res. 16:790–799. 2010.
|
|
40
|
Italiano A, Hostein I, Soubeyran I, et al:
KRAS and BRAF mutational status in primary colorectal tumors and
related metastatic sites: biological and clinical implications. Ann
Surg Oncol. 17:1429–1434. 2010.
|
|
41
|
Han CB, Li F, Ma JT and Zou HW: Concordant
KRAS mutations in primary and metastatic colorectal cancer tissue
specimens: a meta-analysis and systematic review. Cancer Invest.
30:741–747. 2012.
|
|
42
|
Tolmachev V, Stone-Elander S and Orlova A:
Radiolabelled receptor-tyrosine-kinase targeting drugs for patient
stratification and monitoring of therapy response: prospects and
pitfalls. Lancet Oncol. 11:992–1000. 2010.
|
